Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881965 | 0.88 | CYP2C9 (0.75) | CYP1A2CYP2C9CYP2C19L3MBTL1S1PR1 | |
| SCHEMBL8902443 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19L3MBTL1KDR | |
| SCHEMBL5804037 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19EPHX2L3MBTL1 | |
| SCHEMBL21649319 | 0.82 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19EPHX2KDR | |
| SCHEMBL13881966 | 0.80 | CYP1A2 (0.51) | CYP1A2CYP2C9CYP2C19L3MBTL1KDR | |
| SCHEMBL8530877 | 0.80 | AR (0.58) | CYP1A2CYP2C9CYP2C19L3MBTL1KDR | |
| SCHEMBL22954115 | 0.79 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19EPHX2L3MBTL1 | |
| SCHEMBL31495074 | 0.79 | KDR (0.76) | KDRSMN1; SMN2CA1CA2CA9 | |
| SCHEMBL14325837 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19L3MBTL1KDR | |
| SCHEMBL374358 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19L3MBTL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1234695-C | N-alkoxyalkyl-substituted benzimidazoles and use thereof as active agent aginst parasitic protozoans | BAYER AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| US-20040044055-A1 | N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-04 | — | — | US | disclosed |
| CN-1479725-A | N-alkoxyalkyl-substituted benzimidazoles and use thereof as active agent aginst parasitic protozoans | — | 2004-03-03 | — | — | CN | disclosed |
| EP-1326845-A1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030909-A1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044055-A1 | N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans | PIGO, EPX, PIGK | CYP1A2 436/4885CYP2C9 1018/4885CYP2C19 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.